Pacific Shuanglin Bio-pharmacy Co Ltd Class A 000403
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- ¥21.96
- Day Range
- ¥21.90–23.29
- 52-Week Range
- ¥19.46–31.25
- Bid/Ask
- ¥22.81 / ¥22.82
- Market Cap
- ¥16.73 Bil
- Volume/Avg
- 18.0 Mil / 5.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- 21.97
- Price/Sales
- 6.04
- Dividend Yield (Trailing)
- 0.88%
- Dividend Yield (Forward)
- 0.88%
- Total Yield
- 0.88%
Company Profile
Pacific Shuanglin Bio-pharmacy Co Ltd is engaged in the research, development, production, and marketing of blood products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 2,426
- Website
- http://www.999yichun.cn
Comparables
Valuation
|
Metric
|
000403
|
300149
|
300122
|
|---|---|---|---|
Price/Earnings (Normalized) | 21.97 | — | 11.23 |
Price/Book Value | 2.20 | 2.17 | 2.11 |
Price/Sales | 6.04 | 2.76 | 1.43 |
Price/Cash Flow | 18.29 | 22.49 | 9.26 |
Price/Earnings
000403
300149
300122
Financial Strength
|
Metric
|
000403
|
300149
|
300122
|
|---|---|---|---|
Quick Ratio | 2.45 | 1.46 | 1.37 |
Current Ratio | 3.72 | 1.71 | 2.07 |
Interest Coverage | 749.08 | −32.05 | 76.85 |
Quick Ratio
000403
300149
300122
Profitability
|
Metric
|
000403
|
300149
|
300122
|
|---|---|---|---|
Return on Assets (Normalized) | 8.89% | −34.73% | 11.64% |
Return on Equity (Normalized) | 10.33% | −54.47% | 19.62% |
Return on Invested Capital (Normalized) | 8.96% | −38.80% | 17.67% |
Return on Assets
000403
300149
300122
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Swptmpcf | Nyhp | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Zbyxlybs | Rkxcpmh | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Hxdqxtf | Gjgvw | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zqwzjbb | Mwshgwl | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Jwgqrjqf | Pypr | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Srpjkdvd | Phs | $28.0 Bil | |||
| Moderna Inc
MRNA
| Gtzrjpkcq | Mvx | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Tqgqfjm | Vdl | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Kvqdlll | Mcwgm | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Yzslgvjv | Rxfswl | $12.6 Bil |
United States